GlassScriptPhysician profile
Andrew J Croak
NPI 1073581724
$26,292.74
in general payments reported to CMS, 2019-2025
28 companies · $310 in 2025
The $310 reported for 2025 was less than what a typical Urogynecology and Reconstructive Pelvic Surgery (Obstetrics & Gynecology) provider received nationally (typical 2025 total: $413).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $9,138 · 2020: $4,893 · 2021: $5,568 · 2022: $4,269 · 2023: $812 · 2024: $1,302 · 2025: $310.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,352 · Education: $72.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,351.58 |
| Education | $72.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $16,697.76 | 2019-2021 | |
| Axonics, INC. | $4,093.21 | 2020-2024 | Bulkamid, Axonics |
| Medtronic, INC. | $1,473.20 | 2021-2022 | |
| Coloplast Corp | $710.20 | 2019-2025 | Saffron |
| Astellas Pharma US INC | $641.74 | 2019-2024 | Veozah |
| Boston Scientific Corporation | $469.46 | 2019-2025 | Upsylon, Axonics, Bulkamid |
| Abbvie INC. | $308.58 | 2019-2022 | |
| Femselect INC. | $271.31 | 2023-2024 | Enplace |
| Caldera Medical, INC | $178.00 | 2019-2023 | Desara |
| Contura, INC. | $171.23 | 2020 | |
| Abbott Laboratories | $153.53 | 2022 | |
| Ethicon US, LLC | $148.77 | 2019-2025 | Surgicel Nu-Knit, Vistaseal, Evarrest |
| Organogenesis INC. | $147.33 | 2025 | Puraply Wound Matrix |
| Pfizer INC. | $146.27 | 2019-2023 | |
| Myovant Sciences INC. | $118.19 | 2021-2022 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Urovant Sciences INC | $88.37 | 2021-2022 | |
| Sumitomo Pharma America, INC. | $84.68 | 2023 | Gemtesa, Myfembree |
| Therapeuticsmd, INC. | $66.33 | 2019-2020 | |
| Hologic Sales and Service, LLC | $62.18 | 2019-2024 | Fluent Fluid Management System |
| Amgen INC. | $51.56 | 2022 | |
| Allergan, INC. | $46.34 | 2020-2022 | |
| Laborie Medical Technologies Corp. | $36.54 | 2024 | Eclipse |
| Meditrina | $26.42 | 2022 | |
| Smith+Nephew, INC. | $23.23 | 2021 | |
| Exeltis, USA INC. | $23.07 | 2023 | Slynd |
| Access Pro Medical, LLC | $22.20 | 2025 | Matriderm |
| Covidien LP | $21.07 | 2019 | |
| Duchesnay USA Incorporated | $11.97 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Croak listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.